Senior insider sale
Chief Scientific Officer at NURIX THERAPEUTICS, INC. — senior position signals high conviction
$513.1K
22.06K shares
What this filing means
HANSEN GWENN plans to sell 22.06K shares of NURIX THERAPEUTICS, INC. valued at approximately $513.1K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 8/5/2026ACC: 0001950047-26-007704
Officer· Chief Scientific Officer
Since Jul 2020
22.06K
Shares to sell
$513.1K
Approx. market value
8.71K
Acquired (3 months)
1
Planned
3 completed
Securities Acquired — Last 3 Months1
Exercise of Stock Options
Cash
8/5/2026
8.71KTotal acquired8.71K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/5/2026 | Exercise of Stock Options Cash | 8.71K | — |
| Total | 8.71K | ||
Planned & Completed Dispositions4
Completed
—Completed
Units to sell
4.11K
Market value
$100.1K
8/4/2026
—Completed
Units to sell
3.85K
Market value
$90.0K
7/30/2026
—Completed
Units to sell
5.39K
Market value
$107.9K
6/25/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
8.71K
Market value
$215.1K
8/5/2026
Total
Units
22.06K
Value
$513.1K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
8/4/2026 | 4.11K | $100.1K | — | Completed |
7/30/2026 | 3.85K | $90.0K | — | Completed |
6/25/2026 | 5.39K | $107.9K | — | Completed |
| Planned — Approximate Date | ||||
8/5/2026 | 8.71K | $215.1K | NASDAQ | Planned |
| Total | 22.06K | $513.1K | ||